Today's Rundown Daiichi sues Seattle Genetics over tech used in high-profile ADC The top 10 highest paid biopharma R&D executives in 2018 Allogene taps Notch Therapeutics for cell therapy's next chapter: stem cell-based cancer meds [Sponsored] Flip the Funnel: Rethinking Patient Recruitment and Enrollment Strategies Ipsen grabs new R&D lead as Shire's neuro head leaves amid Takeda takeover Takeda bags MD Anderson CAR-NKs, plans 2021 pivotal trial Coda bumps up series A to $34M, lays out first 2 gene therapy programs Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice Stryker to buy orthopedic device maker Wright Medical for $4B Featured Story | | | Tuesday, November 5, 2019 Daiichi Sankyo has started legal action against Seattle Genetics. The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201. |
|
|---|
|
Top Stories Tuesday, November 5, 2019 The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D. Tuesday, November 5, 2019 David Chang and Arie Belldegrun started Allogene last year to embark on the next chapter of CAR-T: allogeneic, or off-the-shelf, treatments. With its latest deal, the company continues to push the envelope—it is teaming up with Canada's Notch Therapeutics on off-the-shelf cell treatments made from stem cells. Monday, November 4, 2019 No matter how successful advertising campaigns are, all that really matters is how many referrals ultimately participate in the trial. It’s time to flip the funnel and focus on converting recruits into enrollees. Tuesday, November 5, 2019 As Japanese pharma Takeda keeps divesting assets, its new big biotech buy Shire keeps divesting research executives. Tuesday, November 5, 2019 Takeda has struck a deal with the MD Anderson Cancer Center to access CAR-NK cell therapies. The deal grants Takeda rights to up to four programs, including natural killer cell therapies aimed at CD19 and BCMA. Tuesday, November 5, 2019 Coda Biotherapeutics launched in September last year with $19 million and a mission to develop gene therapies that can be switched on and off and tuned up and down. Now, the biotech is adding another $15 million to the bank and detailing its first two programs: chronic neuropathic pain and focal epilepsy. Monday, November 4, 2019 Harvard synthetic biology pioneer George Church generated some buzz last year when he co-founded Rejuvenate Bio with the goal of reversing aging with gene therapy. Now, he and his co-founders say they have compelling early evidence in mice that they can use the technology to relieve or reverse Type 2 diabetes, obesity, and heart and kidney failure. Monday, November 4, 2019 Stryker is moving to acquire fellow devicemaker Wright Medical in a $4 billion play to gain a stronger foothold in fast-growing orthopedic segments. Enrollment Showcase Resources Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 